Ebola vaccine trials fast-tracked by international consortium
- Details
- Category: GlaxoSmithKline
A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines aimed at preventing the disease that has killed more than 1,400 people in the current outbreak in west Africa.
Pfizer and Merck to collaborate on study evaluating novel anti-cancer combination regimen
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) and Merck & Co. Inc. (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's crizotinib (XALKORI®) with Merck's investigational anti-PD-1 antibody pembrolizumab,
Roche and InterMune reach definitive merger agreement
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 8.3 billion on a fully diluted basis.
Novartis provides drug candidate compounds to TB Alliance
- Details
- Category: Novartis
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD).
United States Department of Justice closes investigation into PLATO clinical trial for Brilinta
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta (ticagrelor). The government is not planning any further action.
FDA approves Roche's Avastin plus chemotherapy for treatment of advanced cervical cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan for the treatment of women with persistent, recurrent or metastatic carcinoma of the cervix.(1)
Sanofi and MannKind announce global licensing agreement for Afrezza® (insulin human) rapid-acting inhaled insulin
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes.
More Pharma News ...
- Allied Minds and Bristol-Myers Squibb form new enterprise
- Roche to acquire Santaris Pharma to expand discovery and development of RNA-targeting medicines
- Pfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines
- AstraZeneca agrees strategic transaction with Almirall in respiratory disease
- Bayer continues positive business development
- Bristol-Myers Squibb reports second quarter 2014 financial results
- Merck strengthens commitment to Chinese growth market